ChemicalBook > CAS DataBase List > Sutimlimab
Sutimlimab
- Product Name
- Sutimlimab
- CAS No.
- 2049079-64-1
- Chemical Name
- Sutimlimab
- Synonyms
- Sutimlimab;Sutimlimab (DHC43601);Sutimlimab (anti-C1s);Research Grade Sutimlimab(DHC43601)
- CBNumber
- CB68081078
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Sutimlimab Property
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Sutimlimab Chemical Properties,Usage,Production
Biological Activity
Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits the classical complement pathway at C1s, rapidly halted hemolysis in the single-arm CARDINAL study in recently transfused patients with cold agglutinin disease (CAD).
Sutimlimab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Sutimlimab Suppliers
- Tel
- 17754423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8014
- Advantage
- 62
- Tel
- 010-50973130 4009686088
- 3193328036@qq.com
- Country
- China
- ProdList
- 29786
- Advantage
- 68
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1565
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10351
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24647
- Advantage
- 58
- Tel
- 027-65279366 18162686757
- products@biolabreagent.com
- Country
- China
- ProdList
- 9818
- Advantage
- 58
- Tel
- 13720134139 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 5731
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11975
- Advantage
- 58
- Tel
- +86-18521732826
- market@aladdin-e.com
- Country
- China
- ProdList
- 48465
- Advantage
- 58
- Tel
- 13823398779 18670069958
- 313359644@qq.com
- Country
- China
- ProdList
- 3263
- Advantage
- 58
2049079-64-1, SutimlimabRelated Search:
Urelumab
varlilumab
Eptinezumab
Atezolizumab
Obinutuzumab
Utomilumab
Glofitamab
Nesvacumab
Odronextamab
Rituximab